Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SONN - Sonnet BioTherapeutics Holdings, Inc.

IEX Last Trade
1.49
0.030   2.013%

Share volume: 2,897
Last Updated: Thu 26 Dec 2024 08:28:23 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$1.46
0.03
2.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-1.39%
1 Month
-48.74%
3 Months
94.52%
6 Months
51.06%
1 Year
-5.96%
2 Year
29.09%
Key data
Stock price
$1.49
P/E Ratio 
0.00
DAY RANGE
$1.44 - $1.48
EPS 
$0.00
52 WEEK RANGE
$0.71 - $10.02
52 WEEK CHANGE
-$19.33
MARKET CAP 
3.751 M
YIELD 
N/A
SHARES OUTSTANDING 
5.203 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$251,410
AVERAGE 30 VOLUME 
$2,768,023
Company detail
CEO: Pankaj Mohan
Region: US
Website: sonnetbio.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.

Recent news